公开(公告)号：US20190144945A1

公开(公告)日：2019-05-16

申请号：US16248219

申请日：2019-01-15

Applicant: UCB BIOPHARMA SPRL

Inventor： Adam Samuel Platt ,  Stephen Edward Rapecki ,  Mara Fortunato ,  David Robert Rainey ,  John Leigh Rundle ,  Paul Alfred Smith ,  Gillian Fairfull Watt

IPC: C12Q1/6883 ,  G01N33/68 ,  C12Q1/6886

Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.

公开(公告)号：US11466324B2

公开(公告)日：2022-10-11

申请号：US16248219

申请日：2019-01-15

Applicant: UCB BIOPHARMA SPRL

Inventor： Adam Samuel Platt ,  Stephen Edward Rapecki ,  Mara Fortunato ,  David Robert Rainey ,  Jon Leigh Rundle ,  Paul Alfred Smith ,  Gillian Fairfull Watt

IPC: G01N33/68 ,  C12Q1/6883 ,  C12Q1/6886

Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.

公开(公告)号：US10208349B2

公开(公告)日：2019-02-19

申请号：US14084047

申请日：2013-11-19

Applicant: UCB BIOPHARMA SPRL

Inventor： Adam Samuel Platt ,  Stephen Edward Rapecki ,  Mara Fortunato ,  David Robert Rainey ,  Jon Leigh Rundle ,  Paul Alfred Smith ,  Gillian Sairfull Watt

IPC: C12Q1/68 ,  G01N33/68 ,  C12Q1/6883 ,  C12Q1/6886

Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.